Alireza Minagar

Dr. Alireza Minagar

School of Cybersecurity and Information Technology, University of Maryland Global Campus, Adelphi, Maryland, USA

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 May 2026 in Pathophysiology
Verified
Journal Article
Open access
PDF file
Alireza MinagarAlireza Minagar
Alireza Minagar
MSMohammadali Sahraian
Mohammadali Sahraian
Multiple sclerosis (MS) is a chronic, immune-mediated demyelinating disease of the central nervous system whose heterogeneous clinical, radiological, and biological course has long resisted precise individual-level prediction. The recent convergence of large longitudinal datasets, advanced computational methods, and increasingly informative biomarkers has created conditions in which artificial intelligence (AI) and machine learning (ML) can begin to address that problem substantively. This review surveys the current evidence for AI/ML applications across the MS care continuum, with particular focus on the literature from 2022 through early 2026. Nine domains are examined: automated MRI lesion segmentation and quantification, fluid biomarker interpretation, unsupervised disease subtyping, disability progression prediction, treatment response stratification, drug repurposing and molecular discovery, digital biomarker monitoring, mechanistic interpretability, and integrated clinical management protocols. Notable recent contributions include the SuStaIn-based identification of two biologically distinct MS trajectories distinguished by early versus late serum neurofilament light chain elevation, the MindGlide deep learning platform enabling longitudinal analysis of archived routine clinical MRI data, the T-cell morphological classifier predicting natalizumab treatment response before drug initiation, and the fenebrutinib Phase III program that produced the first Bruton’s tyrosine kinase inhibitor results meeting primary endpoints in both relapsing and primary progressive MS. A proposed AI-Enhanced Management Protocol (AMP-26) reflecting 2026 clinical standards is included as an appendix. Throughout, emphasis is placed on mechanistic interpretability: the distinction between models that correlate features with outcomes and models whose decision logic reflects established MS pathobiology is considered a prerequisite for clinical credibility and regulatory readiness.

9 November 2025 in Clinical Neurology and Neurosurgery
Verified
Journal Article
Closed access
Alireza MinagarAlireza Minagar
Alireza Minagar
MSMohammad Ali Sahraian
Mohammad Ali Sahraian

31 August 2026 in Journal of Magnetic Resonance Imaging
Verified
Journal Article
Closed access
EAElnaz Asadollahzadeh
Elnaz Asadollahzadeh
RRReza Razmara
Reza Razmara
VSVahid Shahmaei
Vahid Shahmaei
FSForough Sodaei
Forough Sodaei
ARAli Rezaei
Ali Rezaei
MSMohammad Ali Sahraian
Mohammad Ali Sahraian

23 October 2026 in Archives of Breast Cancer
Verified
Journal Article
Open access
PDF file
JTJamshad Taslimi
Jamshad Taslimi
Alireza MinagarAlireza Minagar
Alireza Minagar
Background: Breast cancer remains the most frequently diagnosed malignancy in women worldwide, and its clinical heterogeneity imposes formidable challenges on treatment standardization and outcome prediction. The emergence of artificial intelligence (AI) and multimodal data integration strategies is fundamentally reshaping how genomic, histopathological, radiological, and electronic health record (EHR) data are synthesized into actionable clinical intelligence.Methods: We conducted a narrative review of peer-reviewed literature published between 2015 and 2026, focusing on AI-driven approaches to genomic profiling, digital pathology, radiomics, natural language processing (NLP) of clinical text, and multimodal data fusion in the context of breast cancer diagnosis, prognosis, and treatment planning.Results: AI-based frameworks have demonstrated superior performance compared with conventional single-modality approaches in subtype classification, treatment response prediction, and biomarker discovery. Deep learning architectures applied to whole-slide imaging, convolutional neural networks in radiomics, graph-based genomic models, and transformer-based NLP pipelines each contribute distinct and complementary dimensions to precision breast oncology. Multimodal fusion models integrating 2 or more data streams consistently outperform unimodal counterparts in prognostic accuracy.Conclusions: Multimodal AI represents a convergent approach capable of operationalizing the biological complexity of breast cancer at the point of clinical care. Realizing this potential requires rigorous prospective validation, harmonized data standards, explainability frameworks, and equitable implementation strategies. Future models must be adaptive, continuously learning, and grounded in real-world clinical evidence.

26 August 2026 in Multiple Sclerosis and Related Disorders
Verified
Journal Article
Closed access
AMAli Ariyaei Motahar
Ali Ariyaei Motahar
MSMohammad Ali Sahraian
Mohammad Ali Sahraian
Alireza MinagarAlireza Minagar
Alireza Minagar

10 November 2026 in Multiple Sclerosis and Related Disorders
Verified
Journal Article
Closed access
AMAli Ariyaei Motahar
Ali Ariyaei Motahar
SNSajad Sahab Negah
Sajad Sahab Negah
MSMohammad Ali Sahraian
Mohammad Ali Sahraian
Alireza MinagarAlireza Minagar
Alireza Minagar